Join a Schizophrenia Treatment Study
We're investigating a study drug to find out how well it works as an add-on therapy in study participants with schizophrenia who did not respond well enough to antipsychotic therapy. Join our compensated study today!
Fast Facts
diagnosed with schizophrenia
receiving antipsychotic medication
history of not responding well to antipsychotic treatments
Compensation Provided For Eligible Participants
Conducted in NYC area
Study Background
Schizophrenia is a complex disorder and is not well understood. However, researchers believe that a combination of genetics and environment contributes to its development. Problems with certain naturally occurring brain chemicals, such as neurotransmitters called dopamine and glutamate, may also be contributors. Current treatment options for schizophrenia include a range of different antipsychotic medications.
Research is underway on a study drug for individuals who still experience symptoms despite treatment with antipsychotic medications.
This study is evaluating the effectiveness of the study drug, valbenazine, compared to a placebo on symptoms of schizophrenia including hallucinations and confused thoughts. Placebos are made of a substance that looks just like the study drug being tested, but they contain no active ingredients.
If you have been diagnosed with schizophrenia and have not responded to antipsychotic treatments in the past, you may qualify for the Journey Study. Find out if you can participate in research today!
Study Background
Schizophrenia is a complex disorder and is not well understood. However, researchers believe that a combination of genetics and environment contributes to its development. Problems with certain naturally occurring brain chemicals, such as neurotransmitters called dopamine and glutamate, may also be contributors. Current treatment options for schizophrenia include a range of different antipsychotic medications.
Research is underway on a study drug for individuals who still experience symptoms despite treatment with antipsychotic medications.
This study is evaluating the effectiveness of the study drug, valbenazine, compared to a placebo on symptoms of schizophrenia including hallucinations and confused thoughts. Placebos are made of a substance that looks just like the study drug being tested, but they contain no active ingredients.
If you have been diagnosed with schizophrenia and have not responded to antipsychotic treatments in the past, you may qualify for the Journey Study. Find out if you can participate in research today!
Additional Information
You may qualify for this study if you meet the following criteria.
Key Criteria:
- 18+ years old
- Diagnosis of schizophrenia
- Receiving antipsychotic medication (except Clozapine)
- History of not responding well to antipsychotic treatments
- Generally healthy (no unstable medical condition, cardiac arrythmia, Parkinson’s, moderate to severe substance abuse)
- Have an adult informant (family member, social worker, caseworker, etc.)
- Willing to comply with all study procedures and restrictions
The total length of participation in the Journey Study is up to 16 weeks, which includes 7 on-site study visits at the 125th Street Clinic in NYC. This study comprises the following periods:
- Come see the clinic, meet the research team, and sign a release of information authorization form
- Screening – This period lasts up to 4 weeks. During this period, the study team performs tests to make sure the study is a good match for the potential participant.
- Treatment period – This period lasts 10 weeks. During this period, participants will take their assigned study treatment of either the study drug or the placebo once daily.
- Follow-up period – This period lasts 2 weeks. During this period, participants will no longer take any study treatment. After 14 days from their last dose of the study treatment, participants will have a final on-site study visit, where the study team will ask questions and check the participant’s health.
